Beta
21 CFR § 520.1447
21 CFR § 520.1447 — § 520.1447 Milbemycin oxime, lufenuron, and praziquantel tablets.
Beta. Legal information, not legal advice. LEGALDIGM is not a law firm. Check the official source for the current text.
Analyze this law with AI§ 520.1447 Milbemycin oxime, lufenuron, and praziquantel tablets.
(a) Specifications. Each tablet contains:
(1) 2.3 milligrams (mg) milbemycin oxime, 46 mg lufenuron, and 22.8 mg praziquantel;
(2) 5.75 mg milbemycin oxime, 115 mg lufenuron, and 57 mg praziquantel;
(3) 11.5 mg milbemycin oxime, 230 mg lufenuron, and 114 mg praziquantel; or
(4) 23 mg milbemycin oxime, 460 mg lufenuron, and 228 mg praziquantel.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use —(1) Dogs —(i) Amount. 0.5 mg milbemycin oxime, 10 mg lufenuron, and 5 mg of praziquantel per kilogram of body weight, once a month.
(ii) Indications for use. For the prevention of heartworm disease caused by Dirofilaria immitis; for the prevention and control of flea populations ( Ctenocephalides felis ); and for the treatment and control of adult roundworm ( Toxocara canis, Toxascaris leonina ), adult hookworm ( Ancylostoma caninum ), adult whipworm ( Trichuris vulpis ), and adult tapeworm ( Dipylidium caninum, Taenia pisiformis, Echinococcus multilocularis, and E. granulosus ) infections in dogs and puppies 2 pounds of body weight or greater and 6 weeks of age and older.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) [Reserved]
[77 FR 4225, Jan. 27, 2012, as amended at 80 FR 18776, Apr. 8, 2015; 83 FR 13635, Mar. 30, 2018; 86 FR 13184, Mar. 8, 2021]
